342
SupramoleculeS in Drug DiScovery anD Drug Delivery: methoDS anD protocolS
Index
M
Macroinitiator �� 140, 143, 147
Macromolecular architecture �� 128, 136, 149
Main transition temperature ��225, 231, 301, 307
Major (M) and minor (m) conformation ��103
Melting temperature ��152, 164, 165, 168, 170, 253
Metastable phases �� 300, 308
Methyl-β-cyclodextrin (M-β-CD) ��165
MGMT expression�� 176, 236
Micellar systems ��316
Mice plasma ��184
Micelles ��71–81, 99–107, 316–322
MicroRNA (miRNA) ��25
Microscope �� 32, 94, 95, 160, 254
Microwave irradiation ��21
Milli-Q water ��130, 132, 133, 136, 142, 144
Mixed nanosystems ��221
Modifications �� 113, 203–206, 258, 275, 287
Molar ratios �� 6–9, 102, 106, 132, 167,
168, 170, 192–194, 224, 227, 228, 230, 241, 258,
259, 266, 267, 276, 300, 304, 307, 310, 318
Molecular docking ��110–113
Molecular dynamics (MD) �� 45–69, 109–123
Molecular homogeneity ��136
Molecular interactions �� 101, 313
Molecular Mechanics Poisson-Boltzmann
Surface Area (MM–PBSA) method �� 111, 117,
118, 122
Molecular modeling ��112–114
Molecular structures �� 9, 35, 50, 251, 313
MTT assays �� 92, 93, 209, 214, 255
Multi-component solutions ��238
Multifunctional drug delivery systems ��136
N
Nanocarriers �� 13, 22, 71, 79, 86, 99, 101, 221,
250, 252, 255, 260
Nanoencapsulation ��207
Nanoparticles (NPs) ��80, 81, 86, 87, 89, 91,
94, 100, 148, 149, 152, 156, 157, 203–208,
210–215, 221, 224, 229, 260, 275, 300, 329
Nanospheres ��86, 153, 155, 204
Nanosponges (NSs) �� 100, 247–279
Nanosystems �� 221, 231, 300
Nanotechnology �� 22, 203
Nanotherapeutics ��279
Nanovesicles ��25
Natural products ��25, 100, 152, 190, 203, 204,
247, 251, 254, 265
N-carboxy Anhydride �� 130–132, 142
Neutralization method �� 8, 318
N
im
–trityl-l-histidine ��130
Nitroxide radical ��101
NMR chromatography �� 238, 239
NMR spectroscopy �� 101, 130, 241–245, 305,
314, 315, 317, 332–335
Non-toxic ��190
Non-reversible Phase ��231
Nuclear magnetic resonance (NMR) �� 9, 129,
178–182, 188, 229, 313–321, 333
Nuclear Overhauser effect (NOE) ��314
O
Organic solvent evaporation �� 73, 81
Organic solvent method ��81
Oxidation �� 14–17, 277, 285–288, 292–296
P
Paclitaxel�� 139, 248, 249
Pancreatic cancer (PC) �� 127, 128, 140
Parkinson’s disease (PD) ��267–268
Paste complexation ��3
PEGylation ��205–206
Pentablock terpolypeptide �� 127, 133, 136
Peptides ��129, 140, 273–276, 315, 316,
328–331, 336
Perturbation �� 46–47, 303–305
pH �� 5–9, 28, 29, 80, 81, 85–90, 96,
128–130, 132, 136, 137, 139, 141––148, 152, 159,
167, 178, 179, 181–183, 185, 190, 193, 194, 209,
210, 212, 214, 222, 223, 227, 230, 237, 241, 249,
251, 252, 254, 255, 262, 268, 274–276, 278, 286,
289, 292, 293, 295, 303, 318, 336
Pharmaceutical applications ��204–206, 248, 265
Pharmaceutical formulations ��152, 164, 165, 204, 206, 208
Pharmaceutical systems ��314
Pharmacological actions ��264
Phase transitions �� 88, 89, 164, 222, 227, 301, 303, 305
Phospholipids �� 222, 226, 227, 230, 231,
299, 300, 304, 308, 320
Physical mixtures �� 164–166, 168, 170–172, 184, 266
Physicochemical characterization �� 73, 224, 231
Physicochemical properties �� 109, 155, 188, 222, 228–229
Physisorption ��271
Plasma stability ��176
Pluronic F-127 ��72–74, 76–81, 264
Poly caprolacton (PLC) ��200
Poly(ethylene oxide) (PEO) ��71–73, 88, 100,
139, 140, 143, 148, 149
Poly(ethylene oxide)-b-poly(ε-caprolactone)
(PEO-b-PCL) ��72, 73, 75–78, 80
Poly(ethylene oxide)-b-poly(propylene oxide)-bpoly(ethylene oxide)
(PEO-b-PPO-b-PEO) �� 71, 72
Poly(lactic-co-glycolic) acid (PLGA) copolymer ��203
Poly(lauryl acrylate) (PLA) �� 225, 229, 230
Poly(N-isopropylacrylamide) (PNIPAM) ��222

- 342/344